Related Experiment Video
Updated: Jun 6, 2026
07:24
Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
Published on: May 25, 2022
[Progress in using Newcastle disease virus for tumor therapy: a review]
Yunzhou Wu1, Jingbo Hao, Deshan Li
1Pharmaceutical Education and Research Office, School of Life Science, Northeast Agricultural University, Harbin 150030, China.
Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology
|November 25, 2010
Summary
Newcastle disease virus (NDV) shows oncolytic potential for cancer therapy. Reverse genetics enhances NDV
Area of Science:
- Virology and Oncology
- Viral Oncolysis
- Cancer Therapeutics
Context:
- Naturally occurring Newcastle disease virus (NDV) exhibits specific oncolytic capabilities.
- Clinical trials indicate promising results for NDV in cancer treatment.
- Reverse genetics technology is increasingly utilized in NDV research.
Purpose:
- To review the advancements in cancer therapy utilizing recombinant NDV.
- To explore the optimization of NDV's oncolytic efficacy through reverse genetics.
- To discuss the application of NDV in clinical cancer therapeutics.
Summary:
- NDV demonstrates significant potential as an oncolytic agent in cancer therapy.
- Reverse genetics enables the optimization of NDV, including F gene modification and expression of therapeutic cytokines (GM-CSF, IFN-gamma, IL-2, TNF-alpha).
- The review covers developments in recombinant NDV for cancer treatment and presents relevant research experiences.
Impact:
- Recombinant NDV holds a promising future for clinical cancer therapeutics.
- Optimized NDV strains may offer novel treatment strategies for various cancers.
- Further research in this domain could lead to improved patient outcomes.
